Tumor antigens for determining cancer therapy
AssigneesBioNTech SE, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
InventorsUgur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Petra Simon, Christoph Hartmann, Stefanie Hubich, Thomas Bukur, Thorsten Litzenberger
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods for cancer treatment involving a specific set of tumor antigens.
Claims13
A method for treating triple negative breast cancer in a patient having triple negative breast cancer, the method comprising:
- (a) determining an expression pattern of a set of tumor antigens in a sample from the patient having triple negative breast cancer, wherein the set of tumor antigens comprises at least one selected from chromosome X open reading frame 61 (CXorf61), Preferentially expressed Antigen in Melanoma (PRAME), and cancer antigen 1 (CAGE1);
- (b) diagnosing the patient having triple negative breast cancer as needing a cancer therapy regimen when at least one tumor antigen selected from CXorf61, PRAME, and CAGE1 is expressed;
- and
- (c) treating the patient having triple negative breast cancer with an immunotherapeutic that targets the at least one tumor antigen expressed in the patient.
A method for preventing or treating triple negative breast cancer in a patient comprising administering to said patient an immunotherapeutic targeting each tumor antigen of a set of tumor antigens, wherein the set of tumor antigens comprises at least one selected from CXorf61, PRAME, and CAGE1.
Dependencies are inferred from the claim text.